San Diego, CA, United States of America

Nicholas D San Martin

This inventor holds 1 USPTO granted patent. Top assignee: Arena Pharmaceuticals, Inc.. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas D San Martin. Retrieved from https://idiyas.com/inventor/nicholas-d-san-martin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Nicholas D San Martin

Introduction

Nicholas D San Martin is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target serotonin receptors. His work is vital for advancing treatments for various central nervous system disorders.

Latest Patents

Nicholas holds a patent for a process that provides intermediates useful in the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine. This compound acts as a serotonin (5-HT) receptor agonist, which is beneficial in treating conditions such as obesity. He has 1 patent to his name, showcasing his innovative approach to pharmaceutical development.

Career Highlights

Nicholas is currently employed at Arena Pharmaceuticals, Inc., where he continues to work on groundbreaking research. His expertise in the field has positioned him as a valuable asset to the company and the broader scientific community.

Collaborations

Throughout his career, Nicholas has collaborated with talented individuals such as Marlon Carlos and Ryan O Castro. These partnerships have fostered an environment of innovation and creativity, leading to advancements in their shared field.

Conclusion

Nicholas D San Martin exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in serotonin receptor research, are paving the way for new treatments for central nervous system disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…